Joshua Brumm

President and Chief Executive Officer

Josh brings extensive healthcare leadership experience to his role at Dyne. Previously, he served as chief operating officer and chief financial officer of Kaleido Biosciences, where he led the company’s financings including its initial public offering and helped bring the lead program into Phase 2 development. Prior to joining Kaleido, Josh was COO and CFO at Versartis, where he oversaw the company’s financial strategy including the successful completion of its IPO, played an integral role in product strategy, and helped negotiate the company’s first product partnership. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics; CFO at ZELTIQ Aesthetics, where he led the company through its initial public offering, led the international product launch for CoolSculpting and also served in corporate development; and director of finance at Proteolix, Inc., assisting in the sale of the company to Onyx Pharmaceuticals. He also held investment banking roles at Citigroup Global Markets, Inc. and Morgan Stanley. Over the course of his career, Josh has raised approximately $1.5 billion in capital. In 2014, he was named Silicon Valley Business Journal’s CFO of the Year for companies under $500 million. He holds a B.A. in business administration from the University of Notre Dame.

Susanna High, MBA

Chief Operating Officer

Susanna has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies. In her most recent position, she served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the company’s severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO®, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Susanna worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Susanna holds an M.S. in economics and business management from Bocconi University in Italy and an M.B.A. from the MIT Sloan School of Management.

Wildon Farwell, M.D., MPH

Chief Medical Officer

Wildon brings expertise in clinical development and medical affairs in neuromuscular diseases and oligonucleotide therapies. He joined Dyne from Biogen, Inc., where he was vice president, global head of neuromuscular diseases, medical affairs. During his 10 years at Biogen, Wildon led the development and life cycle management of SPINRAZA® (nusinersen), an oligonucleotide and the first therapy approved for the treatment of spinal muscular atrophy. He also led the late-stage development of tofersen, an investigational oligonucleotide therapy for amyotrophic lateral sclerosis, oversaw clinical and biomarker development for Biogen’s neuromuscular disease portfolio, and began his tenure at the company leading pharmacovigilance for multiple product candidates. Previously, Wildon was an Assistant Professor in Medicine at Harvard Medical School and a physician at Brigham and Women’s Hospital and the VA Boston Healthcare System. He received his M.D. from the University of Missouri School of Medicine and an MPH in clinical effectiveness from Harvard University School of Public Health.

Oxana Beskrovnaya, Ph.D.

Chief Scientific Officer

Oxana is an accomplished R&D leader with a strong track record of discovering and developing first-in-class therapeutics for rare genetic diseases. She has served as Dyne’s chief scientific officer since June 2021 after joining Dyne as senior vice president, head of research in January 2020. Prior to joining Dyne, Oxana served as head of musculoskeletal and renal research in Sanofi’s rare disease and neurological unit, advancing a pipeline of drug candidates using multiple therapeutic modalities, including nucleic acids, proteins and small molecules. She is the author of numerous patents, invited reviews, editorials, book chapters and original research articles in major scientific journals. Oxana received her Ph.D. in genetics from Moscow Genetics Institute, followed by postdoctoral fellowship training in neuromuscular diseases at the Howard Hughes Medical Institute at the University of Iowa.

Ashish Dugar, Ph.D., MBA

Senior Vice President, Global Head of Medical Affairs

Dr. Dugar brings to Dyne over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Previously, he led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Dr. Dugar joined Intra-Cellular Therapies following his tenure at Roche, where he was global head of clinical development science and innovation and global head of the external development group, including work in oligonucleotides. Previously, he spent 13 years at Pfizer Inc. in various roles, most recently serving as vice president, global head of clinical development and medical affairs of the biosimilars business unit. Dr. Dugar began his career at the National Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health. Dr. Dugar earned an MBA from The Pennsylvania State University and a Ph.D. in pharmacology from The Pennsylvania State University College of Medicine.

Jonathan McNeill, M.D.

Vice President, Business Development

Jonathan brings life science business development and corporate strategy experience to Dyne. Most recently, Jonathan held a business development role at Editas Medicine, where he completed a variety of significant transactions, led strategic planning activities and collaborated on the company’s initial public offering. Prior to Editas, Jonathan was a consultant at the Boston Consulting Group, focusing on the pharmaceutical and biotechnology sectors. He was previously a healthcare services researcher at The University of North Carolina at Chapel Hill. Jonathan earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania and his B.A. in public policy and economics from UNC Chapel Hill, where he was a Morehead-Cain Scholar.

Chris Mix, M.D.

Senior Vice President, Clinical Development

Chris brings extensive clinical development experience to Dyne, most recently serving as vice president of rare genetic disease clinical development at Agios Pharmaceuticals, where he oversaw development across several hemolytic anemia indications. In his previous role as vice president of clinical development at Sarepta Therapeutics, he focused on advancing candidate therapies for rare neuromuscular disease. Chris received his B.A. in chemistry from Haverford College and his M.D. from the University of Massachusetts Medical School. He completed his residency in internal medicine at Tufts Medical Center, a fellowship in nephrology at the Beth Israel Deaconess Medical Center in Boston and an M.S. in clinical care research at the Tufts School of Biomedical Sciences.

John Davis, Ph.D.

Vice President, Head of Preclinical Development

John brings nearly 20 years of experience in a global biopharmaceutical setting with expertise managing both exploratory and GLP nonclinical toxicology studies. John’s breadth of portfolio support includes antisense oligonucleotide, small molecule and biologic programs, across many therapeutic areas and all stages of development. Prior to joining Dyne, John was vice president of preclinical development at Wave Life Sciences where he established toxicology as a core discipline and led cross-functional teams aimed at developing and implementing early safety screening strategies. Prior to Wave, John held positions of increasing responsibility at first Schering-Plough and then Pfizer. While at Pfizer, John was a recognized leader in developing mechanism-based human risk assessment projects and led highly effective cross-discipline teams driving novel approaches to toxicology studies. John received his Ph.D. in molecular toxicology from Purdue University and his B.S. from the University of Wisconsin-Madison.

Gene Kim

Vice President, Finance

Gene brings extensive biotechnology-focused finance experience to his role at Dyne. Previously, he served as vice president of finance at Kaleido Biosciences, where he led the build-out of the company’s financial planning and analysis capabilities. Prior to joining Kaleido, Gene served as senior director of FP&A at Versartis, where he was responsible for the company’s budgeting process, played a key role in the execution of the company’s Initial Public Offering and supported investor relations initiatives. Previously, he served in various roles within the finance organizations at Pharmacyclics, Onyx Pharmaceuticals and Gilead Sciences. Gene began his career in investment banking supporting the Global Healthcare division at Lehman Brothers. He earned a B.A. in electrical engineering from the University of California at Los Angeles.

Amy Reilly

Vice President, Corporate Communications and Investor Relations

Amy brings nearly 20 years of experience in corporate communications in the life science industry to her role at Dyne, including managing investor relations, building employee communications programs, expanding corporate philanthropic initiatives, and executing product launch communications. Prior to joining Dyne, Amy was Vice President, Communications and Investor Relations at Kaleido Biosciences, during which time she helped lead the company’s Initial Public Offering, implemented digital and social media activities as well as oversaw internal and executive communications. Amy previously managed corporate communications at ImmunoGen, led philanthropy and employee communications at Cubist Pharmaceuticals, and held various roles at Biogen, including managing product communications for its multiple sclerosis franchise and media relations, as well as overseeing the company’s Foundation. Amy received her A.B. in English and American Literature from Bowdoin College.

Rick Scalzo

Vice President, Accounting and Administration

Rick brings significant life science and public company finance experience to his role at Dyne. Previously, he served as corporate controller at Kaleido Biosciences, where he played a key role in the execution of the company’s Initial Public Offering and led the accounting group’s transition from private to public company. Prior to joining Kaleido, he served as corporate controller at X4 Pharmaceuticals and Ocata Therapeutics. At Ocata, Rick was a significant contributor to the company’s acquisition by Astellas Pharma and the subsequent integration between the companies. He began his career in public accounting in the Health Industries practice at PricewaterhouseCoopers. Rick is a certified public accountant in the Commonwealth of Massachusetts and received his B.S. in accounting from Boston College and his M.B.A. from University of Massachusetts, Amherst.

Molly White

Vice President, Medical Communications and Advocacy

Molly brings extensive experience in patient advocacy and community engagement to her role at Dyne. She previously served as chief executive officer of the Myotonic Dystrophy Foundation, an organization dedicated to advancing research and enhancing the quality of life of people living with myotonic dystrophy. In that role, she led strategic direction and administrative oversight for the comprehensive programmatic and fundraising efforts of the foundation and its staff. Molly has over 25 years of leadership-level experience building, implementing and running award-winning domestic and international community programs for organizations in both the private and nonprofit sectors. She has created partnerships with a range of governmental, nonprofit and private sector stakeholders to launch initiatives targeting key national issues such as childhood obesity prevention and components of healthcare reform. She received her M.A. from the University of Iowa.

John Najim, MBA

Vice President, Chemistry, Manufacturing and Controls

John brings a wealth of CMC biopharmaceutical development and cGMP manufacturing experience across multiple biologic expression systems and small molecules. John previously held roles of increasing responsibility at Proteon Therapeutics, including most recently as vice president of manufacturing and process development, and also served as associate director of manufacturing at Dyax Corporation. He received his B.S. in biochemistry from Merrimack College and his M.B.A from Bentley University.

Mo Qatanani, Ph.D.

Vice President, Program and Alliance Management

Mo brings extensive experience in developing and advancing multiple therapeutic modalities for metabolic and rare diseases. He was previously director of discovery research at Alexion Pharmaceuticals, where he led drug discovery research programs and collaborations at the company’s Lexington, MA site. Prior to Alexion, Mo led drug discovery at Synageva BioPharma, developing multiple new programs for rare diseases while building and managing a fully externalized research model. Mo began his drug discovery work at the cardiometabolic disease division at Merck Research Laboratories, leading multiple internal programs and strategic partnerships. Mo holds a Ph.D. in molecular and human genetics from Baylor College of Medicine and completed his post-doctoral fellowship at the University of Pennsylvania School of Medicine. He obtained his B.S. and M.S. in biology from the American University of Beirut.

Debra Feldman

Vice President, Head of Regulatory

Debra is an accomplished R&D leader with more than 20 years of regulatory experience in biotech and the life sciences. She has reviewed and authored numerous successful INDs, CTAs, NDAs, MAAs and submissions for breakthrough, fast track, orphan drug and pediatric designations to advance innovative and data-driven science. Prior to joining Dyne, Debra led the regulatory organization at Sage Therapeutics, overseeing regulatory initiatives across a pipeline of products to address neurological and psychiatric disorders. During her time at Sage, she led the company through the approval of ZULRESSO® (brexanolone), the first and only treatment specifically indicated for postpartum depression. Prior to Sage, Ms. Feldman held various regulatory roles focused on multiple therapeutic areas, including rare diseases. Debra holds a B.A. from University of Massachusetts, Amherst, a degree in nutritional science from Simmons College and an M.P.H. from Boston University.

Daniel Wilson

Vice President, Head of Intellectual Property

Dan is an accomplished intellectual property attorney with an extensive knowledge of the pharmaceutical and biotech industries. Prior to joining Dyne, Dan served as senior corporate counsel at Celgene. In that role, he led the intellectual property group for the Massachusetts office while working on a variety of global business deals, collaborations and product development teams. While at Celgene, Dan was patent counsel for project teams that launched two new medicines. Previously, Dan was intellectual property counsel at Sunovion Pharmaceuticals. He began his legal career working at the law firms of Goodwin Procter and Testa, Hurwitz & Thibeault, where he worked with a variety of life science companies. Dan received his B.A. in biology from Swarthmore College, his M.S. in pharmacology from University of Pennsylvania and his J.D. from Boston University School of Law.

Bruce Wentworth, Ph.D.

Senior Scientific Advisor

Bruce has devoted much of his professional life to developing therapies for rare genetic diseases, particularly myopathies. Previously, he was vice president and head of research for Sarepta Therapeutics, leading a team whose work contributed to the FDA approval of Exondys 51, a treatment for Duchenne muscular dystrophy (DMD). Prior to Sarepta, Bruce spent 21 years as a senior research director in the rare disease group at Genzyme (later Sanofi), with a focus on myopathies including DM1,FSHD, DMD and Pompe disease. Bruce currently serves as an independent consultant guiding Dyne and other companies in the preclinical development of therapeutics for rare diseases, as well as in the design of portfolio-based research organizations.

Bruce received his Ph.D. from the University of Massachusetts Medical School and also studied at Harvard Medical School and Boston University Medical School, where he was a fellow of the American Heart Association.